CCB International believes that Corning Jerry Pharmaceutical...

CCB International believes that Corning Jerry Pharmaceuticals is becoming increasingly competitive in the field of NSCLC treatment, and that the reading of KN046-301 trial data that the company had previously postponed and the relevant data updates at ESMO 2023 did not increase the bank's confidence in its successful development of NSCLC treatment.